Spots Global Cancer Trial Database for first in human
Every month we try and update this database with for first in human cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| First in Human Study of AZD9592 in Solid Tumors | NCT05647122 | Advanced Solid ... Carcinoma Non-s... Head and Neck N... Colorectal Neop... | AZD9592 Osimertinib 5-Fluorouracil ... Leucovorin Bevacizumab | 18 Years - | AstraZeneca | |
| A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer | NCT05241613 | Metastatic Cast... | AC176 | 18 Years - | Accutar Biotechnology Inc | |
| A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors | NCT05159700 | Advanced Solid ... Advanced Solid ... | PRJ1-3024 | 18 Years - | Zhuhai Yufan Biotechnologies Co., Ltd | |
| Phase 1 Study of RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors | NCT04053673 | Solid Tumor, Ad... | RBN-2397 | 18 Years - | Ribon Therapeutics, Inc. | |
| A Phase 1 First-in-Human Study Evaluating AMG 900 in Advanced Solid Tumors | NCT00858377 | Advanced Malign... Advanced Solid ... Cancer Solid Tumors Tumors | Arm 1- Dose Esc... Arm 1- Dose Exp... | 18 Years - | Amgen | |
| A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD) | NCT04834778 | Renal Cell Carc... Gastric Cancer Metastatic Brea... Small-cell Lung... Other Solid Tum... | HC-5404-FU | 18 Years - | HiberCell, Inc. | |
| Study of TP-3654 in Patients With Advanced Solid Tumors | NCT03715504 | Advanced Solid ... | TP-3654 | 18 Years - | Sumitomo Pharma America, Inc. | |
| Safety and Tolerability of Intravenous Administration of ICVB-1042 | NCT05904236 | Patients With A... | Treatment with ... | 18 Years - | IconOVir Bio | |
| Phase 1 Study of RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors | NCT04053673 | Solid Tumor, Ad... | RBN-2397 | 18 Years - | Ribon Therapeutics, Inc. | |
| Safety and Tolerability of Intravenous Administration of ICVB-1042 | NCT05904236 | Patients With A... | Treatment with ... | 18 Years - | IconOVir Bio | |
| First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas | NCT03188965 | Advanced Solid ... Non-Hodgkin's L... Mantle Cell Lym... | Elimusertib (BA... | 18 Years - | Bayer | |
| Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid Tumours | NCT04808362 | Advanced Solid ... Pancreatic Canc... CRC | OMO-103 | 18 Years - | Peptomyc S.L. | |
| MCLA-117 in Acute Myelogenous Leukemia | NCT03038230 | Acute Myelogeno... Acute Myeloid L... | MCLA-117 bispec... | 18 Years - | Merus N.V. | |
| First in Human Study of AZD9592 in Solid Tumors | NCT05647122 | Advanced Solid ... Carcinoma Non-s... Head and Neck N... Colorectal Neop... | AZD9592 Osimertinib 5-Fluorouracil ... Leucovorin Bevacizumab | 18 Years - | AstraZeneca | |
| Study of TP-3654 in Patients With Advanced Solid Tumors | NCT03715504 | Advanced Solid ... | TP-3654 | 18 Years - | Sumitomo Pharma America, Inc. | |
| Phase 1 Study of AWT020 in Advanced Cancer | NCT06092580 | Advanced Cancer | AWT020 | 18 Years - | Anwita Biosciences | |
| Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies | NCT04521413 | Advanced Solid ... | CFI-402411 Pembrolizumab | 18 Years - | Treadwell Therapeutics, Inc | |
| MCLA-117 in Acute Myelogenous Leukemia | NCT03038230 | Acute Myelogeno... Acute Myeloid L... | MCLA-117 bispec... | 18 Years - | Merus N.V. | |
| Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/Refractory Acute Leukemia | NCT03957915 | Acute Lymphobla... Acute Lymphobla... Acute Myeloid L... Acute Myeloid L... Mixed Phenotype... | INA03 administr... | 18 Years - | Institut Paoli-Calmettes | |
| Phase 1, First-in-human Study of Oral TP-1287 in Patients With Advanced Solid Tumors | NCT03604783 | Advanced Solid ... Sarcoma Ewing Sarcoma Dedifferentiate... Synovial Sarcom... | TP-1287 | 12 Years - | Sumitomo Pharma America, Inc. | |
| PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors | NCT05233436 | Advanced Solid ... Gastric Cancer Gastroesophagea... Urothelial Canc... Non Small Cell ... Head and Neck S... | PF-07265028 Sasanlimab | 18 Years - 99 Years | Pfizer | |
| A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors | NCT06188208 | Advanced Solid ... Advanced Hemato... | VVD-130850 Pembrolizumab | 18 Years - | Vividion Therapeutics, Inc. | |
| Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies | NCT04521413 | Advanced Solid ... | CFI-402411 Pembrolizumab | 18 Years - | Treadwell Therapeutics, Inc | |
| Phase 1, First-in-human Study of Oral TP-1287 in Patients With Advanced Solid Tumors | NCT03604783 | Advanced Solid ... Sarcoma Ewing Sarcoma Dedifferentiate... Synovial Sarcom... | TP-1287 | 12 Years - | Sumitomo Pharma America, Inc. | |
| PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors | NCT05233436 | Advanced Solid ... Gastric Cancer Gastroesophagea... Urothelial Canc... Non Small Cell ... Head and Neck S... | PF-07265028 Sasanlimab | 18 Years - 99 Years | Pfizer | |
| First in Human Study of AZD9592 in Solid Tumors | NCT05647122 | Advanced Solid ... Carcinoma Non-s... Head and Neck N... Colorectal Neop... | AZD9592 Osimertinib 5-Fluorouracil ... Leucovorin Bevacizumab | 18 Years - | AstraZeneca | |
| Study of TP-3654 in Patients With Advanced Solid Tumors | NCT03715504 | Advanced Solid ... | TP-3654 | 18 Years - | Sumitomo Pharma America, Inc. | |
| Study of TP-3654 in Patients With Advanced Solid Tumors | NCT03715504 | Advanced Solid ... | TP-3654 | 18 Years - | Sumitomo Pharma America, Inc. | |
| A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) | NCT05121948 | Squamous Cell C... Colo-rectal Can... Non Small Cell ... Transitional Ce... Other Solid Tum... Clear Cell Rena... | HC-7366 | 18 Years - | HiberCell, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
